Anifrolumab efficacy and safety by type I IFNGS and clinical subgroups in patients with SLE

Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases
563 بار بازدید - 2 سال پیش - To cite: Vital EM, Merrill
To cite: Vital EM, Merrill JT, Morand EF, et al. Ann Rheum Dis. doi: 10.1136/annrheumdis-2021-221425

Read the full article here: http://dx.doi.org/10.1136/annrheumdis...

Objective: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups.

Conclusions: Overall, this study supports the consistent efficacy and safety of anifrolumab across a range of patients with moderate-to-severe SLE. In a few subgroups, small sample sizes limited conclusions from being drawn regarding the treatment benefit with anifrolumab.

This video summarises a scientific article published by BMJ Publishing Group Limited (BMJ). The content of this video has not been peer-reviewed and does not constitute medical advice.  Any opinions expressed are solely those of the contributors. Viewers should be aware that professionals in the field may have different opinions. BMJ does not endorse any opinions expressed or recommendations discussed. Viewers should not use the content of the video as the basis for any medical treatment. BMJ disclaims all liability and responsibility arising from any reliance placed on the content.
2 سال پیش در تاریخ 1401/01/15 منتشر شده است.
563 بـار بازدید شده
... بیشتر